greeksoup/ stock research

Pfizer (PFE) Q4 FY2024 earnings: revenue $17.8 billion, up 24.7% on the year

Pfizer Inc. (PFE) reported revenue of $17.8 billion for Q4 FY2024, the quarter ended 31 December 2024, up 24.7% on the same quarter a year earlier. Net income was $410 million, and diluted earnings per share $0.07. The figures are the company's own, from the 10-K it filed with the SEC on 27 February 2025.

Revenue
$17.8 billion
+24.7% on the year · +0.3% on the quarter
Q1 FY2023Q4 FY2024
Operating margin
n/a
Q1 FY2023Q4 FY2024
Net income
$410 million
-90.8% on the quarter
Q1 FY2023Q4 FY2024
Diluted EPS
$0.07
-91.0% on the quarter
Q1 FY2023Q4 FY2024

this quarterthe same quarter a year earlierHover a bar for its figure.

Income statement (profit and loss)

$ millionQ4 FY2024Q3 FY2024Q4 FY2023On the quarterOn the yearLast 8 quarters
Revenue17,76317,70214,248+0.3%+24.7%
Cost of revenue5,9095,2637,562+12.3%-21.9%
Gross profit11,85412,4396,686-4.7%+77.3%
Gross margin66.7%70.3%46.9%
Research and development3,0352,5982,815+16.8%+7.8%
Selling, general and administrative4,2743,2444,575+31.8%-6.6%
Interest expense740783688-5.5%+7.6%
Pre-tax income-10.04,715-4,129
Income tax-421234-795
Effective tax raten/a5.0%n/a
Net income4104,465-3,369-90.8%
Net margin2.3%25.2%-23.6%
Diluted EPS$0.07$0.78-$0.60-91.0%
$ million except per share.
Read moreFourth quarters are the year less the first three quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ millionQ4 FY2024Q3 FY2024Q4 FY2023On the quarterOn the yearLast 8 quarters
Operating cash flow6,7216,7145,240+0.1%+28.3%
Capital expenditure9176511,044+40.9%-12.2%
Free cash flow5,8046,0634,196-4.3%+38.3%
Free cash flow margin32.7%34.3%29.4%
Cash from investing-1,623-2,057-10,996
Cash from financing-5,114-4,6365,442
Depreciation and amortisation1,7921,7551,670+2.1%+7.3%
Share-based compensation177274121-35.4%+46.3%
Buybacksn/an/a0.0
Dividends paid2,3802,3802,3150.0%+2.8%
Dividend per sharen/a$0.00n/a
Diluted shares, weighted5,703m5,705m5,647m-0.0%+1.0%
Shares outstanding at period end5,667m5,667m5,647m+0.0%+0.4%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ millionQ4 FY2024Q3 FY2024Q4 FY2023On the quarterOn the yearLast 8 quarters
Shareholders' equity88,20392,28689,014-4.4%-0.9%
Non-controlling interest294272274+8.1%+7.3%
Debt64,35167,70171,888-4.9%-10.5%
Operating lease liabilities2,286n/a2,626-12.9%
Other liabilities58,26259,21762,699-1.6%-7.1%
Total liabilities and equity213,396219,476226,501-2.8%-5.8%
Fixed assets18,39318,54118,940-0.8%-2.9%
Goodwill68,52768,57067,783-0.1%+1.1%
Intangible assets55,41159,98664,900-7.6%-14.6%
Investments13,10917,61119,768-25.6%-33.7%
Cash and equivalents1,0431,0922,853-4.5%-63.4%
Receivables11,46314,45111,177-20.7%+2.6%
Inventory10,85111,72110,189-7.4%+6.5%
Other assets34,59927,50430,891+25.8%+12.0%
Total assets213,396219,476226,501-2.8%-5.8%

Questions

What was Pfizer's revenue in Q4 FY2024?

Pfizer (PFE) reported revenue of $17.8 billion for Q4 FY2024, the quarter ended 31 December 2024, up 24.7% on the same quarter a year earlier.

How much did Pfizer earn in Q4 FY2024?

Net income for Q4 FY2024 was $410 million, and diluted earnings per share $0.07.

When did Pfizer report Q4 FY2024 results?

Pfizer filed its 10-K for the year that ended with the quarter on 27 February 2025; the fourth quarter is the year less the first three.

Quarterly results, the last 20 quarters

Q4 FY2021 * †Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023 †Q2 FY2023 †Q3 FY2023 †Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue23,63525,66127,74222,63824,28918,48613,00713,49114,24814,87913,28317,70217,76313,71514,65316,65417,55714,45115,03416,583
Cost of revenue9,7369,9848,6486,0639,6494,8863,2379,2697,5623,3793,3005,2635,9092,8453,7784,1725,2723,5484,0924,028
Gross profit13,89915,67719,09416,57514,64013,6009,7704,2226,68611,5009,98312,43911,85410,87010,87512,48212,28510,90310,94212,555
Gross margin59%61%69%73%60%74%75%31%47%77%75%70%67%79%74%75%70%75%73%76%
R&D5,9092,3012,8152,6963,6162,5052,6482,7112,8152,4932,6962,5983,0352,2032,4822,5463,2062,4902,8093,016
SG&A4,0992,5933,0483,3914,6453,4183,4973,2814,5753,4953,7173,2444,2743,0313,4153,1864,1622,9613,4113,279
Interest expense314322293311312318508695688790778783740654654652711668667662
Pre-tax income3,8439,05011,4479,0015,2316,2702,269-3,352-4,1293,421-1034,715-10.02,7853,0443,334-1,6433,170-6533,385
Tax rate6%13%14%4%4%11%-3%n/an/a9%n/a5%n/a-7%5%-6%n/a15%n/a4%
Net income3,3937,8649,9068,6084,9945,5432,327-2,382-3,3693,11541.04,4654102,9672,9103,541-1,6472,687-2483,242
Net margin14%31%36%38%21%30%18%-18%-24%21%0%25%2%22%20%21%-9%19%-2%20%
Diluted EPS$0.59$1.37$1.73$1.51$0.87$0.97$0.41-$0.42-$0.60$0.55$0.01$0.78$0.07$0.52$0.51$0.62-$0.29$0.47-$0.04$0.56
Operating cash flow5,9146,5418,1705,9748,5821,212-1,2083,4565,2401,090-1,7816,7146,7212,335-5824,6035,3482,6158355,375
Capital expenditure9936437518411,0011,1399148101,044704637651917564618602845436533573
Free cash flow4,9215,8987,4195,1337,58173.0-2,1222,6464,196386-2,4186,0635,8041,771-1,2004,0014,5032,1793024,802
Buybacks0.02,0000.00.00.00.00.00.00.0n/an/an/an/an/an/an/an/an/an/an/a
Dividends paid2,1892,2492,2442,2452,2452,3032,3152,3142,3152,3722,3802,3802,3802,4372,4452,4442,4452,4452,4512,451
Shares outstanding5,619m5,645m5,646m5,646m5,619m5,645m5,646m5,646m5,647m5,667m5,667m5,667m5,667m5,685m5,686m5,686m5,686m5,699m5,700m5,700m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-K for the period ended 31 December 2024, filed 27 February 2025: the filing.